Linden Thomas Advisory Services »

Denali Therapeutics shares owned by Linden Thomas Advisory Services

Quarter-by-quarter ownership of Denali Therapeutics (DNLI) shares owned by Linden Thomas Advisory Services from 13F filings

Historical chart of Linden Thomas Advisory Services investment in Denali Therapeutics

Tip: Access up to 7 years of quarterly data

All positions including Denali Therapeutics held by Linden Thomas Advisory Services consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Denali Therapeutics by Linden Thomas Advisory Services

Quarter filed Position value Share count Share price at filing
2023-06-30 $578k 20k 29.51
2023-03-31 $443k 19k 23.04
2022-12-31 $508k 18k 27.81

More positions owned by Linden Thomas Advisory Services

Broadcom (AVGO)
salesforce (CRM)
Apple (AAPL)
NVIDIA Corporation (NVDA)
Eli Lilly & Co. (LLY)
Meta Platforms Cl A (META)
Chemed Corp Com Stk (CHE)
Microsoft Corporation (MSFT)
Gartner (IT)
Intuit (INTU)
Lockheed Martin Corporation (LMT)
Netflix (NFLX)
FactSet Research Systems (FDS)
IDEXX Laboratories (IDXX)
Lam Research Corporation (LRCX)

View all positions for Linden Thomas Advisory Services

Top funds holding Denali Therapeutics

Baillie Gifford & Co
Vanguard Group
Wellington Management Company
Crestline Management
Baker Bros. Advisors
T. Rowe Price Associates
Flagship Ventures Management
Bank of New York Mellon
Marshall Wace
Credit Suisse
Federated Investors
Casdin Capital
Gilder, Gagnon, Howe & Co
Norges Bank Investment Management
Yiheng Capital

View all funds holding Denali Therapeutics